Eden Research Valuation
Is 9T7 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 9T7 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 9T7's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 9T7's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 9T7?
Key metric: As 9T7 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 9T7's PS Ratio? | |
|---|---|
| PS Ratio | 4.7x |
| Sales | UK£3.94m |
| Market Cap | UK£18.67m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.5x |
| Enterprise Value/EBITDA | -7.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 9T7's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.7x | ||
IBU IBU-tec advanced materials | 0.7x | 19.2% | €34.2m |
DLX Delignit | 0.3x | 10.3% | €24.2m |
BNN BRAIN Biotech | 1.2x | 8.5% | €68.8m |
SDF K+S | 0.5x | 0.4% | €2.0b |
9T7 Eden Research | 4.7x | 16.0% | €18.7m |
Price-To-Sales vs Peers: 9T7 is expensive based on its Price-To-Sales Ratio (4.7x) compared to the peer average (0.7x).
Price to Sales Ratio vs Industry
How does 9T7's PS Ratio compare vs other companies in the DE Chemicals Industry?
Price-To-Sales vs Industry: 9T7 is expensive based on its Price-To-Sales Ratio (4.7x) compared to the European Chemicals industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is 9T7's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 4.7x |
| Fair PS Ratio | 0.6x |
Price-To-Sales vs Fair Ratio: 9T7 is expensive based on its Price-To-Sales Ratio (4.7x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
UBE
JP¥224.0b
Engages in the chemicals, construction materials, and machinery businesses in Japan, North America, Europe, Africa, the Middle East, Thailand, India, Latin America, and internationally.
UBE
JP¥14.00
7D
-0.7%
1Y
0.7%
Transcontinental
CA$1.4b
Engages in the flexible packaging business in Canada, the United States, Latin America, the United Kingdom, Australia, and New Zealand.
53L
CA$11.10
7D
-1.8%
1Y
53.1%
Trinseo
US$120.4m
Operates as a specialty material solutions provider in the United States, Europe, the Asia-Pacific, and internationally.
3XD
US$3.10
7D
-2.5%
1Y
-48.8%